EMA SPOR SMS — Substance Registration for EU CMC Submissions

EMA SPOR SMS — Substance Registration for EU CMC Submissions

Every EU marketing authorisation holder that has not registered its active substances in EMA’s Substance Management Service is already experiencing submission delays and data reconciliation problems — and most of them don’t yet know it.

That is not a prediction. It is a description of the current state of the EU regulatory environment, and it applies to a far larger share of pharmaceutical portfolios than most regulatory affairs teams are prepared to acknowledge. The European Medicines Agency’s SPOR infrastructure — Substances, Products, Organisations, and Referentials — was not built as an optional enhancement to the EU regulatory framework. It was built as a mandatory data architecture underlying electronic submissions, electronic product information, and variation management across the European Economic Area. Within that architecture, the Substance Management Service — SMS — is the foundational layer. Every product that contains an active substance, every variation that touches a substance attribute, and every ePI record that references a medicinal ingredient depends on a correctly registered and currently valid SPOR SMS substance identifier. Without it, technical validation fails before scientific assessment even begins.

The gap between understanding this conceptually and having it operationalised across a real portfolio is where most EU MAHs currently sit. And that gap has direct, measurable consequences on submission timelines.

WHAT SPOR SMS IS — AND WHAT IT IS NOT

The SPOR Substance Management Service is EMA’s implementation of the ISO 11238 standard for the identification and description of substances used in medicinal products — specifically ISO 11238:2018, the second edition, which cancelled and replaced the original 2012 edition and remains the current, in-force version of the standard. ISO 11238 defines the data model for substances — what constitutes a unique substance identity, how structural characteristics are captured, and how controlled vocabularies must be applied — and EMA’s SMS portal is the operational interface through which those substance records are created, maintained, and queried by pharmaceutical companies, national competent authorities, and EMA itself.

A registered substance in SPOR SMS receives an alphanumeric SPOR substance ID — a persistent, unique identifier assigned upon EMA approval of the submitted substance record. This identifier is not an internal EMA housekeeping code. It is the authoritative EU reference for that substance, and it is the identifier that must appear in electronic Application Forms (eAF), electronic product information (ePI), and IDMP-compliant data submissions. Commission Implementing Regulation (EU) No 520/2012, Articles 25 and 26, establishes the underlying legal obligation for MAHs, national competent authorities, and EMA to use ISO IDMP standards, and EMA’s Product Management Services (PMS) Implementation Guide for ISO IDMP standards (EMA/795140/2018) is explicit on the operational consequence: compliant submissions require SPOR-derived identifiers, not proprietary company codes, not legacy EU data fields, and not UNII numbers obtained from the FDA’s Unique Ingredient Identifier system.

This last point — the distinction between FDA UNII and EMA SPOR SMS identifiers — is a persistent source of confusion that I encounter in regulatory due diligence work and in portfolio gap assessments. The FDA’s UNII system and EMA’s SPOR SMS are separate databases governed by separate regulatory frameworks, built on overlapping but not identical data models, and they serve different regulatory jurisdictions. A UNII code does not substitute for a SPOR substance ID in EU submissions. A substance that is registered in the FDA’s Global Substance Registration System may or may not have a corresponding SPOR SMS record, and even when both records exist, the identifiers are not interchangeable in submission documents. Companies that have built their global regulatory data infrastructure around UNII as the primary substance identifier must perform a systematic UNII-to-SPOR cross-reference exercise before those records can support EU submission workflows.

THE REGISTRATION PROCESS: DATA REQUIREMENTS AND WHAT APPLICANTS CONSISTENTLY GET WRONG

The SPOR SMS registration process is executed through the EMA SMS portal. The applicant — which may be the MAH, a regulatory affairs consultant acting on behalf of the MAH, or in some cases a pharmaceutical company that has not yet obtained a marketing authorisation but anticipates doing so — submits a substance record that must satisfy the data requirements defined in EMA’s SPOR SMS documentation and in the ISO 11238:2018 standard.

For small molecule chemical entities, the required data elements are well-defined. The substance name must be provided using a controlled name — INN (International Nonproprietary Name) where one exists, otherwise a common name or IUPAC-derived name — and that name must match the controlled vocabulary in the EMA Referentials Management Service. The molecular formula must be provided. Molecular weight must be specified — and here the submission must include both the average molecular weight (the mass-weighted average over natural isotopic abundances) and the monoisotopic molecular weight (calculated from the most abundant isotope of each element). These are not interchangeable values and submitting only one, or confusing which is which, is a common data quality error that slows initial processing. The InChI string — the International Chemical Identifier, developed by IUPAC and NIST — must be provided for small molecules as the machine-readable structural representation. The CAS Registry Number, where one is assigned by the Chemical Abstracts Service, provides an important cross-reference. Substance type must be declared: chemical, biological, radiopharmaceutical, herbal, or other defined categories in the SPOR controlled vocabulary.

For biological substances, the data requirements are substantially more complex. Protein-based biologicals require sequence data. Glycoproteins require glycosylation profile information. Complex mixtures — certain vaccines, plasma-derived products, herbal extracts — have their own defined data models within ISO 11238:2018 and the EMA SMS documentation. It is precisely this complexity that drives the variation in registration timelines. A well-documented small molecule substance submitted with complete, accurately formatted data can move through EMA review in five to fifteen business days. Complex biological substances, particularly those requiring EMA scientific review because the data submitted requires expert evaluation of the structural characterisation package, can take considerably longer — and in some cases the SMS registration process for a novel complex biological involves an iterative data exchange with EMA reviewers before the record is approved and the SPOR substance ID is assigned.

The practical implication is that SPOR SMS registration for complex biologicals cannot be treated as a last-minute submission task. If a company is preparing a variation application affecting the active substance of a complex biological product, and the SMS substance record is not already current and correctly registered, the timeline for completing SMS registration must be incorporated into the variation preparation plan, not treated as a parallel activity that can be resolved concurrently with submission.

THE SUBMISSION FAILURE MECHANISM THAT TEAMS UNDERESTIMATE

The eAF technical specifications require a valid SPOR substance ID for all active substances referenced in the application form. This is not a soft requirement. The eAF validation rules perform a technical check against the SPOR SMS database. If the substance ID submitted in the eAF is missing, if it references a substance record that has not been approved, or if the ID does not match the substance data in the eAF (for example, if the substance name in the form does not correspond to the name in the SPOR record), the form fails technical validation. A form that fails technical validation is rejected before it reaches the scientific assessment queue. The submission is returned to the applicant for correction, the submission clock does not start, and the variation timeline is extended by however long it takes to resolve the data issue and resubmit.

This is not a theoretical failure mode. It is the actual mechanism by which SPOR data gaps translate into variation submission delays — and because the technical validation failure happens at the portal level rather than during scientific review, it can take regulatory teams by surprise, particularly those who are accustomed to working with legacy paper-based processes where substance identification was handled through text fields rather than controlled-vocabulary identifiers.

EU GMP Annex 13, while primarily addressing investigational medicinal products, reinforces the broader principle that data integrity in regulatory submissions extends to the accuracy of substance and product identification data. The obligation to maintain accurate, current regulatory data records is not confined to the commercial product stage, and good regulatory data management practice — analogous to good manufacturing practice for physical product quality — requires that substance records in SPOR SMS be treated as controlled data that must be verified, maintained, and updated as part of the product lifecycle management program.

─────────────────────────────────────────────── FRAMEWORK BOX: XGene SPOR SMS Registration and Lifecycle Management Program ───────────────────────────────────────────────

The XGene SPOR SMS Registration and Lifecycle Management Program addresses SPOR substance data as a portfolio-level regulatory asset requiring systematic management across six operational components:

Portfolio Audit for SPOR SMS Registration Status. A structured review of every active substance across the EU product portfolio to determine whether a current, approved SPOR SMS substance ID exists for each, whether that ID is consistent with the current approved product data, and whether the substance record reflects the current characterisation state of the substance.

Substance Registration Data Package Preparation. For substances without a current valid SPOR SMS record, preparation of the complete data package required for SMS portal submission — substance name, molecular formula, average and monoisotopic molecular weight, InChI string, CAS number, substance type designation, and for biologicals the sequence and glycosylation profile data required by ISO 11238:2018.

Submission to EMA SMS Portal with Timeline Tracking. Managed submission of substance registration packages to the EMA SMS portal, with tracking of review status, management of EMA queries during the review process, and timeline integration with variation submission planning to ensure SMS approvals are in place before variation eAF submission.

UNII-to-SPOR Cross-Reference Table. For companies with FDA UNII-based substance registries, development and maintenance of a cross-reference table mapping each UNII identifier to its corresponding SPOR SMS substance ID, flagging substances where a SPOR record does not yet exist or where data discrepancies exist between the two registries.

Variation Impact Assessment for Substance Changes Requiring SMS Update. A defined assessment process to identify, at the point of variation scoping, whether any proposed change to an active substance — structural modification, new salt or ester form, change to specification, change to characterisation data — requires an update to the SPOR SMS substance record before or concurrent with variation submission.

SPOR Data Stewardship Governance. Defined roles and responsibilities for SPOR SMS data ownership, with designated data stewards per substance or product family, defined review frequency for registered substance records, and a change control process for substance data updates.

───────────────────────────────────────────────

THE OPERATIONAL POSTURE THAT PROTECTS SUBMISSION TIMELINES

The companies that do not experience SPOR-related submission delays are not the ones that have resolved individual submission problems as they arise. They are the ones that have treated SPOR SMS substance registration as a portfolio management program — audited once completely, maintained systematically, and integrated into the variation management workflow so that substance data status is verified at the point of variation scoping rather than at the point of submission. The difference between those two approaches is, in practice, the difference between a variation that reaches scientific assessment on its first submission and one that cycles through technical validation failures for weeks before the data issues are resolved.

The EMA’s IDMP implementation program is continuing to mature, and the expectation that SPOR data must be accurate, current, and consistently applied across all submission types is not a transitional requirement that will relax as the system matures. It is the permanent state of EU regulatory submissions. Building the internal capability and data governance infrastructure to manage SPOR SMS systematically is not optional work for EU MAHs. It is the baseline operational requirement for maintaining a functioning EU regulatory submission program.

Pull your EU product portfolio and identify every active substance — then check whether each substance has a valid SPOR SMS substance ID registered in the EMA system, and whether that ID is consistently used in all current eAF submissions for products containing that substance.